324 related articles for article (PubMed ID: 23818708)
1. Dactylitis in psoriatic arthritis: prevalence and response to therapy in the biologic era.
Gladman DD; Ziouzina O; Thavaneswaran A; Chandran V
J Rheumatol; 2013 Aug; 40(8):1357-9. PubMed ID: 23818708
[TBL] [Abstract][Full Text] [Related]
2. Risk of Subsequent Infection Among Patients Receiving Tumor Necrosis Factor Inhibitors and Other Disease-Modifying Antirheumatic Drugs.
Accortt NA; Bonafede MM; Collier DH; Iles J; Curtis JR
Arthritis Rheumatol; 2016 Jan; 68(1):67-76. PubMed ID: 26359948
[TBL] [Abstract][Full Text] [Related]
3. Treatment of Dactylitis and Enthesitis in Psoriatic Arthritis with Biologic Agents: A Systematic Review and Metaanalysis.
Mourad A; Gniadecki R
J Rheumatol; 2020 Jan; 47(1):59-65. PubMed ID: 30824641
[TBL] [Abstract][Full Text] [Related]
4. MRI changes in psoriatic dactylitis--extent of pathology, relationship to tenderness and correlation with clinical indices.
Healy PJ; Groves C; Chandramohan M; Helliwell PS
Rheumatology (Oxford); 2008 Jan; 47(1):92-5. PubMed ID: 18077498
[TBL] [Abstract][Full Text] [Related]
5. Treatment patterns and health care costs for patients with psoriatic arthritis on biologic therapy: a retrospective cohort study.
Zhu B; Edson-Heredia E; Gatz JL; Guo J; Shuler CL
Clin Ther; 2013 Sep; 35(9):1376-85. PubMed ID: 23954091
[TBL] [Abstract][Full Text] [Related]
6. Hospitalizations of patients treated with anti-tumor necrosis factor-α agents -- a retrospective cohort analysis.
Zisman D; Haddad A; Hashoul S; Laor A; Bitterman H; Rosner I; Eder L; Balbir-Gurman A; Mader R; Milman U
J Rheumatol; 2013 Jan; 40(1):16-22. PubMed ID: 23070992
[TBL] [Abstract][Full Text] [Related]
7. Clinical Characteristics, Disease Activity, and Patient-Reported Outcomes in Psoriatic Arthritis Patients With Dactylitis or Enthesitis: Results From the Corrona Psoriatic Arthritis/Spondyloarthritis Registry.
Mease PJ; Karki C; Palmer JB; Etzel CJ; Kavanaugh A; Ritchlin CT; Malley W; Herrera V; Tran M; Greenberg JD
Arthritis Care Res (Hoboken); 2017 Nov; 69(11):1692-1699. PubMed ID: 28376239
[TBL] [Abstract][Full Text] [Related]
8. Sustained benefits of infliximab therapy for dermatologic and articular manifestations of psoriatic arthritis: results from the infliximab multinational psoriatic arthritis controlled trial (IMPACT).
Antoni CE; Kavanaugh A; Kirkham B; Tutuncu Z; Burmester GR; Schneider U; Furst DE; Molitor J; Keystone E; Gladman D; Manger B; Wassenberg S; Weier R; Wallace DJ; Weisman MH; Kalden JR; Smolen J
Arthritis Rheum; 2005 Apr; 52(4):1227-36. PubMed ID: 15818699
[TBL] [Abstract][Full Text] [Related]
9. Hemostatic and fibrinolytic changes are related to inflammatory conditions in patients with psoriatic arthritis--effect of different treatments.
Di Minno MN; Iervolino S; Peluso R; Di Minno A; Ambrosino P; Scarpa R;
J Rheumatol; 2014 Apr; 41(4):714-22. PubMed ID: 24532831
[TBL] [Abstract][Full Text] [Related]
10. Treatment of psoriatic arthritis with biological agents.
Ceponis A; Kavanaugh A
Semin Cutan Med Surg; 2010 Mar; 29(1):56-62. PubMed ID: 20430309
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and tolerability of anti-tumour necrosis factor therapy in psoriatic arthritis patients: results from the South Swedish Arthritis Treatment Group register.
Kristensen LE; Gülfe A; Saxne T; Geborek P
Ann Rheum Dis; 2008 Mar; 67(3):364-9. PubMed ID: 17644547
[TBL] [Abstract][Full Text] [Related]
12. Incidence of Malignancies in a Cohort of Psoriatic Arthritis Patients Taking Traditional Disease Modifying Antirheumatic Drug and Tumor Necrosis Factor Inhibitor Therapy: An Observational Study.
Costa L; Caso F; Del Puente A; Di Minno MN; Peluso R; Scarpa R
J Rheumatol; 2016 Dec; 43(12):2149-2154. PubMed ID: 27633825
[TBL] [Abstract][Full Text] [Related]
13. The comparative effectiveness of anti-TNF therapy and methotrexate in patients with psoriatic arthritis: 6 month results from a longitudinal, observational, multicentre study.
Heiberg MS; Kaufmann C; Rødevand E; Mikkelsen K; Koldingsnes W; Mowinckel P; Kvien TK
Ann Rheum Dis; 2007 Aug; 66(8):1038-42. PubMed ID: 17213251
[TBL] [Abstract][Full Text] [Related]
14. Time and predictors of response to tumour necrosis factor-alpha blockers in psoriatic arthritis: an analysis of a longitudinal observational cohort.
Eder L; Chandran V; Schentag CT; Shen H; Cook RJ; Gladman DD
Rheumatology (Oxford); 2010 Jul; 49(7):1361-6. PubMed ID: 20385615
[TBL] [Abstract][Full Text] [Related]
15. Long-term work disability in patients with psoriatic arthritis treated with anti-tumour necrosis factor: a population-based regional Swedish cohort study.
Kristensen LE; Englund M; Neovius M; Askling J; Jacobsson LT; Petersson IF
Ann Rheum Dis; 2013 Oct; 72(10):1675-9. PubMed ID: 23148309
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of new treatments for dactylitis of psoriatic arthritis: update of literature review.
Sondag M; Verhoeven F; Guillot X; Prati C; Wendling D
Clin Rheumatol; 2019 Feb; 38(2):591-596. PubMed ID: 30328022
[TBL] [Abstract][Full Text] [Related]
17. Psoriatic arthritis.
Wollina U; Unger L; Heinig B; Kittner T
Dermatol Ther; 2010; 23(2):123-36. PubMed ID: 20415819
[TBL] [Abstract][Full Text] [Related]
18. The Swedish Early Psoriatic Arthritis Registry 5-year Followup: Substantial Radiographic Progression Mainly in Men with High Disease Activity and Development of Dactylitis.
Geijer M; Lindqvist U; Husmark T; Alenius GM; Larsson PT; Teleman A; Theander E
J Rheumatol; 2015 Nov; 42(11):2110-7. PubMed ID: 26472410
[TBL] [Abstract][Full Text] [Related]
19. Clinical response, drug survival, and predictors thereof among 548 patients with psoriatic arthritis who switched tumor necrosis factor α inhibitor therapy: results from the Danish Nationwide DANBIO Registry.
Glintborg B; Ostergaard M; Krogh NS; Andersen MD; Tarp U; Loft AG; Lindegaard HM; Holland-Fischer M; Nordin H; Jensen DV; Olsen CH; Hetland ML
Arthritis Rheum; 2013 May; 65(5):1213-23. PubMed ID: 23460467
[TBL] [Abstract][Full Text] [Related]
20. Predictors of early minimal disease activity in patients with psoriatic arthritis treated with tumor necrosis factor-α blockers.
Iervolino S; Di Minno MN; Peluso R; Lofrano M; Russolillo A; Di Minno G; Scarpa R
J Rheumatol; 2012 Mar; 39(3):568-73. PubMed ID: 22247361
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
